Belén Garijo, Merck KGaA CEO (Arne Dedert/picture-alliance/dpa/AP Images)
March 27, 2023 03:28 PM EDT
Deals
Pharma

Mer­ck KGaA takes back con­trol of PD-L1 can­cer drug as Pfiz­er al­liance ends

Paul Schloesser

Associate Editor

Mer­ck KGaA re­port­ed Mon­day that it had re­gained full rights to its PD-L1 an­ti­body Baven­cio af­ter a near­ly 10-year al­liance with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times